tiếng anh giao tiếp tập 2
Báo cáo y học: "Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study" pdf
... men) 21 50 ± 12 (24 -76) 70 ± 13 (47-97) 10% 30 50 ± 12 (22 -71) 72 ± 15 (47-104) 20 % 21 53 ± 11 (25 -68) 69 ± 18 (43-108) 10% 28 52 ± (38-76) 75 ± 22 (47- 120 ) 21 % 100 51 ± 11 (22 -76) 72 ± 17 (43- 120 ) ... Tender joint count 21 .3 ± 12. 3 (6- 62) 21 .4 ± 13.1 (5-58) 23 .2 ± 16.8 (4-63) 24 .1 ± 13.4 (6-53) 22 .5 ± 13.7 (4-63) FACIT-F (0- 52) 26 ± 11 (4-50) 26 ± 10 (4-50) 27 ± 12 ( 12- 50) 26 ± 11 (4-50) SF-36 ... interleukin-16 Visvanathan et al Arthritis Research & Therapy 20 10, 12: R211 http://arthritis-research.com/content/ 12/ 6/R211 22 23 24 25 26 27 28 29 30 Page 11 of 11 expression in synovial fibroblasts...
- 11
- 329
- 0
Báo cáo y học: "Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study" pps
... 84.4 46 .2 43.3 66.8 24 .9 50.7 37 .2 69.3 30.3 57.1 34 .2 69.1 27 .5 63.4 30.1 74 .2 42. 5 64.1 26 .7 70.1 52. 2 39.0 49.8 61 .2 38.3 52. 4 38.5 61.5 38.4 40 .2 28.9 62. 4 75.6 12. 5 11.9 64.0 20 .9 15.1 62. 4 ... 0. 32 (0.41) 0.09 (0 .25 ) 0.10 (0 .25 ) 0.16 (0. 32) 0 .27 (0.39) 0.43 (0.45) 0.30 (0. 42) 0 .27 (0.40) 0.16 (0. 32) 0.05 (0.18) 0.07 (0 .22 ) 0.07 (0 .23 ) 0.08 (0 .23 ) 0.04 (0.17) 0.05 (0.19) 0.07 (0 .22 ) ... 0.00 02 < 0.0001 < 0.0001 < 0.0001 1.658 0.5 72 0.974 1 .26 1 1.663 1.157 1 .23 7 1.034 0.746 1.018 0.965 4.956 2. 097 8.630 0.944 1. 120 1.145 1 .23 2 to 2. 2 32 0 .24 3 to 1.343 0.701 to 1.3 52 0.9 12 to 1.744...
- 10
- 379
- 0
Báo cáo y học: "Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis" pot
... Repopulation 8. 62 n.d 1.56 9 .20 5.06 n.d 93.9 1 .24 6.65 Recovery 11.9 2. 45 1 .24 22 .7 4.49 65 .2 2 .21 5.50 12 months after repopulation 1. 62 40.9 6.46 24 months after repopulation APRIL (ng/ml) 0.04 ... 3. 42 0. 92 0.75 1.33 1.31 1.90 2. 30 1.08 4 .27 7.90 n.d 2. 62 n.d 4.06 3. 12 3.51 4.41 months post-treatment 5.88 6.34 4.46 2. 83 1.59 Baseline 409 77.8 189 5.04 96.7 124 179 23 .7 39.5 Depletion 4 12 ... S14 S16 S17 S19 S20 27 /F 56/F 33/F 50/F 33/F 33/F 19/F 35/F 56/F 51/F Baseline 25 14 12 22 14 12 Depletion 11 13 10 n.d 16 11 12 n.d months post-treatment 11 13 n.d n.d Baseline 2 15 18 8 Depletion...
- 10
- 485
- 0
Báo cáo y học: " Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients" potx
... 5,634 21 ,580 1 ,24 6 72, 539 42, 536 2, 156,097 184,713 163,435 11,869
- 12
- 128
- 0
Báo cáo hóa học: " Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab" doc
... 100 Male 62 61 Female 39 39 Median age (years range) 63 (26 -80) Gender Performance Status 79 78 20 20 >1 2 Colon 79 78 Rectum 22 22 Liver metastases 79 78 77 76 >1 24 24 43 42 1 -2 40 40 >2 18 18 ... 3.15) 0.03 2. 20 (1.03 4.70) 0.04 Number of Lines: II-III vs I 2. 20 (1 .25 - 3.89) 0.01 4.60 (1.87 11.31) 0.001 EGFR score: 0-1 vs 2- 3 2. 27 (1.35 - 3. 82) 0.0 02 1.99 (0.89 4.44) 0.09 - - 2. 14 (0.97 ... Cetuximab CPT-11 19 19 CPT-11, L-OHP, 5-FU 29 29 FOLFIRI 21 21 FOLFOX 20 20 Only Cetuximab 12 12 Campanella et al Journal of Translational Medicine 20 10, 8:36 http://www.translational-medicine.com/content/8/1/36...
- 8
- 472
- 0
Báo cáo y học: "Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turk
... 26 (4) Lesion length, 21 (3) mme Type of lesion, No (%) A (3) Bı 52 (45) B2 12 (10) C 49 ( 42) Paclitaxelb (n:101) P Valuec 76 (75) (9) 16 (16) 67.4 (7.3) 31 (5) 369 056 506 28 (8) 22 (7) 2 (2) ... drug-eluting http://www.medsci.org Int J Med Sci 20 11, 12 13 14 15 16 17 18 19 20 21 22 23 73 versus bare-metal stents J Am Coll Cardiol, 20 06; 48: 25 84– 25 91 Mauri L, Hsieh WH, Massaro JM, Ho KK, ... Glucose 127 .2 ( 62. 7) Paclitaxelb (n:101) 58 (10 .2) P Valuec 36 (36) 64 (63) 55 (54) 69 (68) (7) (6) (3) 34 (34) 47 (47) 20 (20 ) 5 23 3.8 (57.4) 150.3 (48.4) 39.4 (8.3) 158.6 (101 .2) 114.7 (46.4) 5 2...
- 6
- 550
- 0
Tài liệu Differences in 4-Year Health Outcomes for Elderly and Poor, Chronically III Patients Treated in HMO and Fee-for-Service Systems ppt
... -4.6 36 45.7 822 1413 X2 =14.1 53 -1.9 -2. 9 to -0.9 26 58 17 47.6 0.7 -1.1 to 2. 5 17 60 23 15 48.8 1 .2 0.4 to 2. 0 15 64 21 489 44.4 -3.6 -5 .2 to -2. 0 33 1746 45 .2 -2. 9 -3.7 to -2. 1 27 58 50.3T ... to -3.4 28 63 Nonelderly Prepaid (HMO) 1413 727 45.8 (0.5) -1 .2 -2. 6 to 0 .2 23 X 2= 2.3 62 16 46.9 (0.6) 1.5 0.1 to 2. 9 12 X z =2. 6 68 Fee-for-service 686 45.6 (0.5) -2. 4 -3.8 to -1.0 29 57 15 ... Nonpoverty 22 35 45.0 Average Scores -3.0 Baseline* 4-y At 48.5 1.1 Categorical Change, %t 95% CI§ Worse Same Better 15 63 22 0.0 to 2. 4 14 X2 =1 3_ 64 22 -0.4 to 2. 4 16 63 21 0.3 to 1.9 11 X24.3 43.5§...
- 9
- 621
- 0
Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India pot
... Ͻ0.001 2. 5 (1.4–4.6) 455 51 (11 .2) 32 10 (31 .2) 3.6 (1.5–8.5) Ͻ0.01 4.8 (2. 0–11.6) 403 49 ( 12. 2) 100 13 (13.0) 1.1 (0.5 2. 2) 22 4 27 ( 12. 1) 27 9 35 ( 12. 5) 1.0 (0.6–1.8) 24 1 33 (13.7) 24 8 27 (10.9) ... 39 (11.6) 1 .2 (0.7 2. 3) P value aOR (95%CI) 0.1 0 .2 0.7 0.5 26 0 19 (7.3) 22 6 41 (18.1) 2. 8 (1.5–5 .2) Ͻ0.001 326 30 (9 .2) 160 30 (18.8) 2. 3 (1.3–4.1) Ͻ0.01 329 28 (8.5) 1 62 32 (19.8) 2. 6 (1.5–4.7) ... 2 , 3ϩ Initial weight Ͻ 42 kg у 42 kg Relapse n (%) 380 52 (13.7) 123 10 (8.1) OR (95%CI) 1.8 (0.8–3.9) 26 1 27 (10.3) 24 2 35 (14.5) 1.5 (0.8 2. 6) 20 9 24 (11.5) 27 7 36 (13.0) 1 .2 (0.6 2. 1) 150 21 ...
- 6
- 532
- 0
Báo cáo hóa học: " Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients" pot
... [36.4] [28 .6] 49 55 Gender Age (median) paraprotein subtype G 0.99 [27 .3] [64.3] [9.1] [21 .4] D [18 .2] [0] LC [45.5] [14.3] I & II [63.6] [50] III [36.4] [50] [27 .3] [57.1] [ 72. 7] [ 42. 9] No [9.1] ... author declares that they have no competing interests Received: 27 July 20 10 Accepted: 26 November 20 10 Published: 26 November 20 10 References Chim CS, Hwang YY, Pang C, Shek TW: Restoration ... [45.5] [28 .6] [54.5] 10 [71.4] [27 .3] [7.1] ISS stage ≥VGPR after induction No Yes 0.69 0 .22 7 ≥VGPR after ABMT 0.03 Oligoclonal reconstitution Yes no DAPK methylation methylated 0.434 0 .21 6 unmethylated...
- 7
- 489
- 0
Báo cáo hóa học: "DNA polymeraseh protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy" pot
... Female 31 38.7 36 42 45.0 52. 5 2 2.5 Cardia 21 26 .3 Body 18 22 .5 Antrum/pylorus 41 51 .2 Liver Lung 26 21 32. 5 26 .3 Peritoneum 19 23 .8 Others 14 17.4 G1 2. 5 G2 26 32. 5 G3 52 65.0 treatment response ... Translational Medicine 20 10, 8: 126 http://www.translational-medicine.com/content/8/1/ 126 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 versus best supportive care (BSC) as 2nd-line chemotherapy ... 0.889 0.308 0. 929 0. 525 2% 0.500 0.889 0.340 0.940 0.588 3% 0.645 0.889 0. 421 0.9 52 0.700 4% 0. 823 0.889 0.593 0.9 62 0.838 5% 0.887 0.889 0.696 0.965 0.888 6% 0.887 0.778 0.667 0.9 32 0.863 Treatment...
- 9
- 610
- 0
báo cáo hóa học:" Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients" pdf
... 116 (27 %) 53 (28 %) 63 (26 %) years 76 (17%) 31 (16%) 45 (18%) years years 143 (56%) 83 ( 32% ) 70 (56%) 40 ( 32% ) 73 (55%) 43 ( 32% ) years 61 (24 %) 27 (22 %) 34 (26 %) years 43 (17%) 17 (14%) 26 (19%) ... IIC 27 (6%) 10 (5%) 17 (7%) IIIA, IIIB 82 (19%) 26 (14%) 56 (23 %) IIIC IV 27 7 (64%) 49 (11%) 136 (71%) 19 (10%) 141 (58%) 30 ( 12% ) 87 (20 %) 35 (18%) 52 (21 %) ≤ cm 141 ( 32% ) 77 (40%) 64 (26 %) ... 1.0 IV - 2. 76 [1.44,5 .27 ] 0.0 02 Residual tumour size 1.0 1.0 ≤ cm 1 .23 [1 .22 ,4.07] 0.009 2. 23 [1.06,4.67] 0.033 > cm 3.41 [1.88,6.18] 0.000 2. 99 [1.45,6.17] 0.003 Grade Grade 1.0 2. 92 [1.45,5.86]...
- 9
- 407
- 0
báo cáo hóa học:" Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs" potx
... and long terminal repeat sequences over years in vivo and in vitro J Virol 1991, 65 :22 5 -23 1 22 23 24 25 26 27 28 Fitzgibbon JE, Mazar S, Dubin DT: A new type of G > A hypermutation affecting human ... E44D (0) K219Q (7.8) Q151M (3.9) T215F (11.7) T215Y (33.3) RT (NNRTI) (n = 12) V108I (25 ) Y181C (33.3) G190S (0) P236L (0) Y188C (0) V106A (0) K103N (9.6) Y188H/L (16.6) M230L (0) P 225 H (0) L100I ... CG GC K20R (2. 9) I47V (2. 9) L10F (0) V82A/S (17.6) I47V (0) L10I (17.6) L10R (5.8) G48V (11.7) L24I (0) K20M (2. 9) L10V (5.8) M46L (0) D30Na (14.7) I50V (0) L90M (47) M46L (17.6) I54M (2. 9) G73S...
- 6
- 286
- 0
báo cáo hóa học: " F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)" pdf
... (2. 9-4.8) [24 .7%] 350 [68.9%] 22 5 [29 .6%] 74.6 (54.7-98) 78 129 66.7 (51.3-76.7) [89.4%] 92 [117.9%] 85 [65.9%] 57 [73.1%] 70 [54.3%] 25 .3 (20 .6 -29 .5) [ 92% ] 20 .3 (11 -25 ) [91%] 674 [ 122 .3%] 53 [59.6%] ... 31.3 (26 .5-40.5) [67.5%] 21 0 [56.8%] 47 [39.8%] 22 .1 (16.7 -28 .2) [47.6%] 20 7 [55.9%] 53 [44.9%] B (superscan) 15.0 (13 .2- 17 .2) 508 761 16.0 (11.9 -21 .1) [106.7%] 459 [90.4%] 3 32 [43.6%] 3.7 (2. 9-4.8) ... 607 [110 .2% ] 50 [56 .2% ] 27 3 [107.5%] 406 [103.3%] 38 .2 (26 .5-46.9) [51 .2% ] 30.7 (21 .1-59.4) [111.6%] 18.8 (9.8 -24 .8) [84.3%] 29 8 [117.3%] 29 0 [73.8%] C3, L1, L5, L femur, R tibia C (6 -20 L1, L3,...
- 6
- 286
- 0
Báo cáo y học: "Primary Care Outcomes in Patients Treated by Nurse Practitioners or Physicians" docx
... 31 (20 .5) 21 (20 .8) 2 = 0.144 27 (17.9) 21 (20 .8) 63 (41.7) 42 (41.6) 82 (54.3) 23 (15 .2) 56 (55.4) 21 (20 .8) 20 (13 .2) (7.9) 26 (17 .2) 16 (15.8) 108 (71.5) 28 (18.5) 79 (78 .2) 17 (16.8) 2 = ... 6.1 9 .2 22. 9 2 = 1.033 P = 31 27 .7 54.5 8.9 6.3 22 .4 66 .2 20.4 17.7 7.4 8.6 6.5 2 = 1.703 P = 19 16.5 65.8 2 = 0. 428 P = 51 54.8 13.9 22 .8 2 = 0.678 P = 41 7.5 91.5 90 .2 8.5 9.8 2 = 0 .26 5 ... ( 42. 88) 32. 28 (43.53) Bodily pain 38.10 (29 . 72) 39 .25 (29 .36) t = −0 .23 1 P = 82 t = 0.306 P = 76 General health 38.06 (23 . 02) 37.08 (23 .48) t = −0.333 P = 74 Vitality 43.06 (25 .21 ) 42. 43 (25 .14)...
- 10
- 411
- 0
Báo cáo y học: "Brain choline concentrations may not be altered in euthymic bipolar disorder patients chronically treated with either lithium or sodium valproate" pps
... 0 .22 0.30 0 .27 0 .25 0 .23 0 .22 0 .2 0 .28 0 .23 0 .24 0 .27 0.35 0.33 0 .24 0 .24 0 .24 0 .22 0 .28 0.16 0 .28 0 .29 0 .26 0 .26 F M F F M F F F F 2. 72 2.61 2. 03 2. 44 2. 60 2. 07 2. 78 1.76 2. 43 2. 38 2. 1 3. 42 ... 3.51 2. 19 3.01 2. 11 2. 47 1.91 1.76 1.88 1.94 1. 82 1. 72 2 .21 2. 95 3.03 2. 31 2. 72 2.34 1.76 2. 36 1.51 2. 14 2. 52 2 .23 2. 35 6.67 10.1 9.97 7.94 9.98 8 .28 7.93 9.56 7.04 7.8 7.16 8.40 8.53 9.11 9. 52 ... 1.88 2. 53 2. 77 1.89 2. 93 2. 27 2. 40 9.16 8.17 8.56 9.93 7.84 9 .26 8.35 7 .26 7.75 8.48 10.13 10.53 7.48 8.19 7.51 10.39 9.79 8.01 7 .23 8.81 0.30 0. 32 0 .24 0 .25 0.33 0 .22 0.33 0 .24 0.31 0 .28 0 .21 ...
- 7
- 430
- 0
Báo cáo y học: "Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept" pot
... 13.7 (2. 5–41.0) 36 (1–85) 11.3 (5.5–19 .2) 12. 2 (8.1 29 .7) DAS28 at baselinea 5.3 (2. 4–8.1) 5.9 (3.7–7.5) HAQ at baselinea 1.4 (0.4 2. 8) 1.6 (0.3 2. 8) Monotherapy/combination therapy 5 /27 3/14 ... No 32 Age (years)a 56.7 (23 .5–80.9) Female/male Duration of disease 25 /7 (years)a Serum CRP at baseline (mg/l)a Serum COMP at baseline (u/l)a 12. 9 (3.0–55.5) 20 (1–84) Etanercept 17 55.3 (23 .2 70.4) ... trial Ann Intern Med 20 02, 136:1- 12 Correspondence Tore Saxne, Department of Rheumatology, Lund University Hospital, S -22 1 85 Lund, Sweden Tel: +46 46 171 627 ; fax: +46 46 128 468; e-mail: tore.saxne@reum.lu.se...
- 5
- 486
- 0
Báo cáo y học: "Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical respone" pot
... treatment (n) 2. 78 ± 1.41 2. 70 ± 2. 70 0.47 Swollen joint count (0 28 ) 4.57 ± 3.16 4.55 ± 2. 70 0.43 Tender joint count (0 28 ) 9 .21 ± 5.78 8.35 ± 6.07 0.80 DAS28 score 5.33 ± 1. 12 5.31 ± 1.19 0.76 ... 37.59 ± 23 .18 37.45 ± 23 .71 0.91 CRP (mg/l) 26 .93 ± 24 .87 31.30 ± 27 .24 0.65 Values are expressed as mean ± standard deviation CRP, C-reactive protein; DAS28, Disease Activity Score 28 ; DMARD, ... 0.97) Similar results were observed with p55 (25 34 ± 1074 pg/ml versus 24 36 ± 953 pg/ml; P = 0.57) and p75 (3054.8 ± 673.8 pg/ml versus 23 32. 2 ± 921 .3 pg/ml; P = 0.84) soluble receptors in good...
- 7
- 453
- 0
Báo cáo y học: "Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs" ppsx
... (22 .7) 23 (57.5) 57 (37.5) 2. 25 (1.11–4.58) Low/Low 22 4 (65.3) 12 (30.0) 75 (49.7) Referent Low/High 68 (19.8) 22 (55.0) 44 (29 .1) 3.13 (1.41–6. 92) 0.005 4 .20 (1.66–10.63) 0.0 02 High/Low 41 ( 12. 0) ... -1,0 82 IL-10 Low (AA/AG) 29 2 (85.1) 34 (85.0) 119 (78.8) Referent Referent High (GG) 51 (14.9) (15.0) 32 (21 .2) 0.66 (0 .25 –1.70) Low (GG) 26 5 (77.3) 17 ( 42. 5) 95 ( 62. 5) Referent High (AA/GA) 78 (22 .7) ... None/NSAIDS (26 .1) 17 (73.9) (17.4) 19 ( 82. 6) Antimalarials 23 (57.5) 17 ( 42. 5) (15.0) 34 (85.0) Corticosteroids (28 .6) 20 (71.4) (22 .2) 21 (77.8) Antimalarials and corticosteroids 25 (41.7) 35...
- 9
- 347
- 0
Báo cáo khoa học: "Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients" pot
... -2. 5 -2. 4 0.66§ 0.0 02 Diarrhea Grade I 17 (55) 29 (91) Grade II, III 14 (45) (9) 0.03¶ Anti diarrhea drug used No 21 (68) 29 (91) Yes 10( 32) 3(9)
- 6
- 261
- 0
Báo cáo khoa học: "Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy" pot
... 0.759-8.995 0. 128 V35 2. 313 0.751-7. 122 0.144 V40 2. 485 0 .29 2 -21 .1 52 0.405 V45 1 .21 9 0.373-14.146 0.475 V50 1.613 0 .22 9 -22 . 824 0.318 V55 1.446 0 .21 5 -20 .061 0.594 V60 1.139 0.070-18.6 12 0. 527 COPD 0.154 ... 1.835-56. 024 0.008 MLD 3.199 0.196- 52. 380 0.415 V5 4. 024 0.765 -21 .163 0.100 V10 9. 023 1.910- 42. 625 0.005 V15 4. 024 0.765 -21 .163 0.100 V20 2. 801 0.834-9.403 0.096 V25 3. 423 0.713-16. 421 0. 124 V30 2. 613 ... 6.03 x = 28 . 02, SD = 7.09 0.0 02 V25 12. 96% (5.90 -26 .26 %) x = 12. 88, SD = 4. 42 x = 20 .91, SD = 6.98 0.001 V30 10.00% (4.68 -21 .43%) x = 9. 72, SD = 3.45 x = 15.69, SD = 6.00 0.008 V35 9. 92% (3.89-18.65%)...
- 8
- 371
- 0
Tìm thêm: xác định các mục tiêu của chương trình khảo sát các chuẩn giảng dạy tiếng nhật từ góc độ lí thuyết và thực tiễn khảo sát chương trình đào tạo của các đơn vị đào tạo tại nhật bản tiến hành xây dựng chương trình đào tạo dành cho đối tượng không chuyên ngữ tại việt nam điều tra đối với đối tượng giảng viên và đối tượng quản lí điều tra với đối tượng sinh viên học tiếng nhật không chuyên ngữ1 khảo sát thực tế giảng dạy tiếng nhật không chuyên ngữ tại việt nam nội dung cụ thể cho từng kĩ năng ở từng cấp độ xác định mức độ đáp ứng về văn hoá và chuyên môn trong ct phát huy những thành tựu công nghệ mới nhất được áp dụng vào công tác dạy và học ngoại ngữ mở máy động cơ lồng sóc mở máy động cơ rôto dây quấn các đặc tính của động cơ điện không đồng bộ hệ số công suất cosp fi p2 đặc tuyến hiệu suất h fi p2 đặc tuyến dòng điện stato i1 fi p2 động cơ điện không đồng bộ một pha thông tin liên lạc và các dịch vụ từ bảng 3 1 ta thấy ngoài hai thành phần chủ yếu và chiếm tỷ lệ cao nhất là tinh bột và cacbonhydrat trong hạt gạo tẻ còn chứa đường cellulose hemicellulose chỉ tiêu chất lượng 9 tr 25